AI
TRVI icon

Atom Investors’s Trevi Therapeutics TRVI Stock Holding History

Atom Investors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,996
Closed -$151K – 785
2025
Q1 		$151K Buy
+23,996
New +$114K 0.02% 413
2024
Q2 		– Sell
-45,736
Closed -$158K – 673
2024
Q1 		$158K Buy
45,736
+6,088
+15% +$13.6K 0.02% 499
2023
Q4 		$53.1K Buy
39,648
+1,128
+3% +$1.71K 0.01% 433
2023
Q3 		$84K Buy
38,520
+143
+0.4% +$323 0.02% 409
2023
Q2 		$91.7K Buy
38,377
+3,906
+11% +$9.84K 0.03% 267
2023
Q1 		$63.8K Buy
34,471
+9,095
+36% +$20.6K 0.03% 235
2022
Q4 		$49K Buy
+25,376
New +$50K 0.02% 207

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Atom Investors's TRVI Position: Q2 2025 in Review

Atom Investors sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 23,996 shares — an estimated $151K sold.

Atom Investors first reported a position in TRVI in Q4 2022 and held it in 7 quarters. The position peaked at $158K in Q1 2024. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • Atom Investors reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Atom Investors sold 23,996 Trevi Therapeutics shares in Q2 2025, an estimated $151K.
  • Atom Investors first reported a position in Trevi Therapeutics in Q4 2022 and held it in 7 quarters.
  • Atom Investors's Trevi Therapeutics position peaked at $158K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Atom Investors's 13F filing for Q2 2025, filed 14 Aug 2025.